Pluri's Cellav Secures UK Regulatory Nod for Regenativo+, Eyes $900M Market
PLUR is trading near its 52-week low of $1.56 (12% above the low).
Summary
Pluri's subsidiary Cellav completed UK cosmetic regulatory registration for its regenerative aesthetics product Regenativo+, enabling commercial launch in a market estimated at ~$900 million annually. This follows the U.S. product listing in June and marks another step in the company's global commercialization push. The news provides a tangible regulatory milestone amid Pluri's acute liquidity crisis—the company had less than three months of cash as of May and faces Nasdaq delisting. While the UK approval is a positive development, the company's near-term survival hinges on resolving its $27.4 million EIB loan and securing additional financing. Commercial discussions with UK clinics and distributors are underway, but revenue contribution remains uncertain.
At the time of this announcement, PLUR was trading at $1.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.7M. The 52-week trading range was $1.56 to $5.68. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.